L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-&alpha; 2b plus ribavirin

doi:10.3748/wjg.v17.i39.4414

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5936)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

469

HTML

5016

Figures (1-1)

228

Tables (1-2)

223

Sum=5936

Oct 21, 2011 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 21, 2011; 17(39): 4414-4420
Published online Oct 21, 2011. doi: 10.3748/wjg.v17.i39.4414

Open in New Tab Full Size Figure Download Figure

Figure 1 Trial profile of L-carnitine treatment. IFN-α: Interferon α; HCV: Hepatitis C virus; RBV: Ribavirin; SVR: Sustained virological responders; ETR: End-of-treatment responders.

Citation: Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420
URL: https://www.wjgnet.com/1007-9327/full/v17/i39/4414.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i39.4414